Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide

Journal of Physiology and Pharmacology

Volumn 59, Issue 4, 2008, Pages 673-689

  Engel, Matthias A ^a   Kellermann, C A ^a   Rau, T ^a   Burnat, G ^a   Hahn, E G ^a   Konturek, P C ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Anandamide; Cannabinoids; Colitis; IBD; TNBS

Indexed keywords

ANANDAMIDE; CYTOKINE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; MOUSE; NONHUMAN; ULCERATIVE COLITIS;

ANIMALS; ARACHIDONIC ACIDS; COLITIS, ULCERATIVE; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED AKR; POLYUNSATURATED ALKAMIDES; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID;

EID: 58449083070     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991; 325: 928-937.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991; 325: 1008-1016.
3. Hollander D. Inflammatory bowel diseases and brain-gut axis. J Physiol Pharmacol 2003; 54 Suppl 4: 183-190.
4. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006; 20: 568-570.
5. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-1592.
6. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118(2 Suppl 1): S68-S82.
7. Sartor RB. Animal models of intestinal inflammation. Relevance to inflammatory bowel disease. In Inflammatory bowel disease. New York, Elsevier Science. 1991; pp. 337-353.
8. Massa F, Sibaev A, Marsicano G, Blaudzun H, Storr M, Lutz B. Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. J Mol Med 2006; 84: 142-146.
9. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
10. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin. Investig. Drugs 2003; 12: 39-49.
11. Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell. Biochem 2003; 88: 462-466.
12. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111-119.
13. Dembinski A, Warzecha Z, Ceranowicz P et al. Cannabinoids in acute gastric damage and pancreatitis. J Physiol Pharmacol 2006; 57 Suppl 5: 137-154.
14. Abel EL. Marijuana: the first twelve thousand years. New York, Plenum Press. 1980, pp. 289.
15. Grispoon L, and Bakalar JB. Marijuana: the forbidden medicine. New Haven, Yale University Press 1997, pp. 184.
16. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-867.
17. Keates AC, Castagliuolo I, Cruickshank WW et al. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology. 2000; 119: 972-82.
18. Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol Motil. 2004; 16: 811-818.
19. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 2006; 1: 581-585.
20. Harsch IA, Brzozowski T, Bazela K, et al. Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines. Eur J Pharmacol 2003; 481: 249-260.
21. Konturek PC, Brzozowski T, Sulekova Z, Meixner H, Hahn EG, Konturek SJ. Enhanced expression of leptin following acute gastric injury in rat. J Physiol Pharmacol 1999; 50: 587-595.
22. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002; 448: 410-422.
23. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-234.
24. Jaggar SI, Sellaturay S, Rice AS. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci. Lett 1998; 253: 123-126.
25. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134: 563-570.
26. Izzo, AA, Mascolo N, and Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001; 1: 597-603.
27. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
28. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992; 89: 3825-3829.
29. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78: 43-50.
30. Scroggs RS, Fox AP. Distribution of dihydropyridine and omega-conotoxin-sensitive calcium currents in acutely isolated rat and frog sensory neuron somata: diameter-dependent L channel expression in frog. J Neurosci 1991; 11: 1334-1346.
31. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276(6 Pt 2): H2085-H2093.
32. Hemmings HC Jr, Nairn AC, McGuinness TL, Huganir RL, Greengard P. Role of protein phosphorylation in neuronal signal transduction. FASEB J 1989; 3: 1583-1592.
33. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-1209.
34. Diaz-Granados HK, Lu J, McKay DM. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000; 156: 2169-2177.
35. Egger B, Bajaj-Elliott M, MacDonald TT, et al. Characterization of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000; 62: 240-248.
36. Hosseini JM, Goldhill JM, Bossone C, Pineiro-Carrero V, Shea-Donohue D. Progressive alterations in circular smooth muscle contractility in TNBS-induced colitis in rats. Neurogastroenterol Motil 1999; 11: 347-356.
37. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13: 420-423.
38. Eisenstein TK, Meisler JJ, Wilson Q, Gaughan JP, Adler MW. Anandamide and Delta9-tetrahydrocannbinol directly inhibit cells of the immune system via CB2-receptors. J Neuroimmunol 2007; 189: 17-22.
39. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 377-391.
40. Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 2003; 17: 2611-2618.
41. Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates colera toxin-induced fluid accumulation in mice. Gastroenterology 2003; 125: 765-774.
42. McVey DC, Schmid PC, Schmid HH, Vigna SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 2003; 304: 713-722.
43. Smith SR, Denhardt G, Terminelli C. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur J Pharmacol 2001; 432: 107-119.
44. Storr M, Sibaev A, Marsicano G, et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 2004; 286: G110-G117.
45. De Man JG, Moreels TG, De Winter BY, et al. Disturbance of the prejunctional modulation of cholinergic neurotransmission during chronic granulomatous inflammation of the mouse ileum. Br J Pharmacol 2001; 133: 695-707.
46. Herradon E, Martín MI, Lopez-Miranda V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 2007; 152: 699-708.
47. Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflam Bowel Dis 2003; 9: 179-189.
48. Grisham MB, Pavlick KP, Laroux FS, Hoffman J, Bharwani S, Wolf RE. Nitric oxide in chronic gut inflammation: controversies in inflammatory bowel disease. J Invest Med 2002; 50: 272-283.
49. Guihot G, Guimbaud R, Bertrand V, et al. Inducible nitric oxide activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn's disease. Amino Acids 2000; 18: 229-237.
50. Menchen LA, Colon AL, Moro MA, et al. N-(3-(aminomethyl)benzyl) acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulfonic acid in rats. Life Sci 2001; 69: 479-491.
51. Kankuri E, Vaali K, Knowles RG, et al. Supression of acute experimental colitis by a highly selective inducible nitric oxide synthase inhibitor, N-{3-(aminomethyl)benzyl}acetamidine. J Pharmacol Exp Ther 2001; 298: 1128-1132.
52. Vardareli E, Dundar E, Angin K, Saricam T, Inal M. Effects of intrarectal and intraperitoneal NG-nitro-L-arginine methyl ester treatment in 2,4,6-trinitrobenzene sulfonic acid induced colitis in rats. Exp Toxicol Pathol 2003; 55: 271-276.
53. Armstrong AM, Campbell GR, Gannon C, Kirk SJ, Gardiner KR. Oral administration of inducible nitric oxide synthase inhibitors reduces nitric oxide synthesis but has no effect on the severity of experimental colitis. Scand J Gastroenterol 2000; 35: 832-838.
54. Dikopoulos N, Nussler AK, Liptay S, et al. Inhibition of nitric oxide synthesis by aminoguanidine increases intestinal damage in the acute phase of rat TNB-colitis. Eur J Clin Invest 2001; 31: 234-239.
55. Yoshida Y, Iwai A, Itoh K, et al. Role of inducible nitric oxide synthase in dextran sulfate sodium-induced colitis. Aliment Pharmacol Ther 2000; 14 Suppl 1: 26-32.
56. Rumi G, Tsubouchi R, Nishio H, Kato S, Mozsik G, Takeuchi K. Dual role of endogenous nitric oxide in development of dextran sodium sulfate-induced colitis in rats. J Physiol Pharmacol 2004; 55: 823-836.
57. Hokari R, Kato S, Matsuzaki K, et al. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis. Free Radic Biol Med 2001; 31: 153-163.
58. Aoi Y, Terashima S, Ogura M, Nishio H, Kato S, Takeuchi K. Roles of nitric oxide (NO) and NO synthases in healing of dextran sulfate sodium-induced rat colitis. J Physiol Pharmacol 2008; 59: 315-336.